Next-generation of selective histone deacetylase inhibitors

被引：94

作者：

Yang, Feifei ^{[1
,2
,3
]}

Zhao, Na ^{[1
]}

Ge, Di ^{[1
]}

Chen, Yihua ^{[2
,3
]}

机构：

[1] Univ Jinan, Sch Biol Sci & Technol, Jinan 250022, Shandong, Peoples R China

[2] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai 200241, Peoples R China

[3] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China

来源：

RSC ADVANCES | 2019年 / 9卷 / 34期

基金：

中国国家自然科学基金;

关键词：

DIVERSITY-ORIENTED SYNTHESIS; BIOLOGICAL EVALUATION; HDAC INHIBITORS; CANCER-THERAPY; MOLECULAR-MECHANISMS; ISOFORM SELECTIVITY; EPIGENETIC THERAPY; ACID-DERIVATIVES; RATIONAL DESIGN; ACTIVITY ASSAY;

D O I：

10.1039/c9ra02985k

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of cancers. First-generation inhibitors are mainly pan-HDACis that target multiple isoforms which might lead to serious side effects. At present, the next-generation HDACis are mainly focused on being class- or isoform-selective which can provide improved risk-benefit profiles compared to non-selective inhibitors. Because of the rapid development in next-generation HDACis, it is necessary to have an updated and state-of-the-art overview. Here, we summarize the strategies and achievements of the selective HDACis.

引用

页码：19571 / 19583

页数：13

共 50 条

[21] Mechanisms of selective anticancer action of histone deacetylase inhibitors
Insinga, A
Minucci, S
Pelicci, PG
CELL CYCLE, 2005, 4 (06) : 741 - 743
[22] Isoform-specific histone deacetylase inhibitors: The next step?
Balasubramanian, Sriram
Verner, Erik
Buggy, Joseph J.
CANCER LETTERS, 2009, 280 (02) : 211 - 221
[23] From discovery to the coming generation of histone deacetylase inhibitors
Yoshida, M
Matsuyama, A
Komatsu, Y
Nishino, N
CURRENT MEDICINAL CHEMISTRY, 2003, 10 (22) : 2351 - 2358
[24] THE NEXT-GENERATION OF CHOLINESTERASE-INHIBITORS
ADEM, A
ACTA NEUROLOGICA SCANDINAVICA, 1993, 88 : 10 - 12
[25] BETting on next-generation bromodomain inhibitors
Collins, Matthew K.
Chau, Cindy H.
Price, Douglas K.
Figg, William D.
AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2020, 8 (04): : 129 - 132
[26] Histone deacetylase inhibitors
Miller, TA
Witter, DJ
Belvedere, S
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (24) : 5097 - 5116
[27] Histone deacetylase inhibitors
Sharma, S.
LUNG CANCER, 2006, 54 : S51 - S51
[28] Histone Deacetylase Inhibitors
Ramalingam, Suresh S.
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (11) : S1808 - S1809
[29] Histone deacetylase inhibitors
Grant, S
ANNALS OF ONCOLOGY, 2005, 16 : 29 - 29
[30] Histone deacetylase inhibitors
Monneret, C
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2005, 40 (01) : 1 - 13

← 1 2 3 4 5 →